MedCap AB (publ) OMXSTO:MCAP:
ABILIA ACQUIRES LIVASSURED
PURCHASE PRICE INCLUDES 9.5 MEUR INITIAL PAYMENT
POTENTIAL ADDITIONAL PAYMENT UP TO 4 MEUR BASED ON PROFIT GROWTH
ACQUISITION EXPECTED TO POSITIVELY IMPACT MEDCAP'S EARNINGS
Abilia Acquires Livassured
Earlier from MedCap
- MCAP: Q2 2025 delivered double-digit sales and EBITA growth, with strong M&A momentum
- MedCap's Business Area Specialty Pharma Completes the Acquisition of XGX Pharma
- MedCap's Business Area Specialty Pharma Acquires XGX Pharma
- MCAP: Q1 2025 delivered 7% sales growth, 17% EBITA margin, and strong M&A prospects
- MCAP: Achieved SEK 1,807 million revenue in 2024 with a 23% EBITA CAGR, driven by acquisitions
Later from MedCap
- MCAP: Q3 2025 delivered 21% sales growth, 32% EBITA growth, and strong segment performance
- MCAP: Life science group achieves robust growth via acquisitions and innovation in core business areas
- MCAP: Record sales and EBITA growth in 2025, supported by strong operations and acquisitions
- MedCap (Q4 review): Beat on Solid Organic Growth
- MCAP: Q1 2026 delivered double-digit revenue and profit growth, driven by strong segment performance
Follow MedCap into a list and get an email when it puts out news.
Follow MedCap